このアイテムのアクセス数: 186

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s12886-019-1104-3.pdf3.75 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorNoda, Kazunorien
dc.contributor.authorOishi, Akioen
dc.contributor.authorUji, Akihitoen
dc.contributor.authorTanaka, Saorien
dc.contributor.authorTsujikawa, Akitakaen
dc.contributor.alternative野田, 和誉ja
dc.contributor.alternative大石, 明生ja
dc.contributor.alternative宇治, 彰人ja
dc.contributor.alternative田中, 沙織ja
dc.contributor.alternative辻川, 明孝ja
dc.date.accessioned2019-05-14T02:22:53Z-
dc.date.available2019-05-14T02:22:53Z-
dc.date.issued2019-04-24-
dc.identifier.issn1471-2415-
dc.identifier.urihttp://hdl.handle.net/2433/241357-
dc.description.abstractBackground: The optimal treatment of serpiginous choroiditis is not established. While recent reports indicate the efficacy of adalimumab, there is limited evidence. We present a case of serpiginous choroiditis refractory to steroids, immunosuppressants, and adalimumab. Case presentation: An 18-year-old woman presented with severe vision loss in both eyes. A fundus examination revealed a foveal grayish-white lesion, and optical coherence tomography revealed outer retinal damage. She was diagnosed with serpiginous choroiditis and treated with steroid pulse therapy, but the disease progressed continuously. The addition of sub-Tenon’s injection of triamcinolone and oral cyclosporine did not change the disease course. We also administered subcutaneous injections of adalimumab, but even with the intensive treatment, the retinal lesions and subsequent atrophy progressed. Her right and left visual acuity declined from 20/22 to 20/66 and 20/200, respectively, during the 9 months of follow-up. Conclusion: Here, we report a case of serpiginous choroiditis refractory to corticosteroids, immunosuppressants, and adalimumab. Further studies are needed to establish the optimal treatment for such cases.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer Natureen
dc.publisherBMCen
dc.rights© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectSerpiginous choroiditisen
dc.subjectChorioretinal degenerationen
dc.subjectGeographic choroiditisen
dc.subjectGeographic choroidopathyen
dc.subjectPosterior uveitisen
dc.subjectRelentless placoid chorioretinitisen
dc.subjectSerpiginous choroidopathyen
dc.titleLimited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case reporten
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleBMC Ophthalmologyen
dc.identifier.volume19-
dc.relation.doi10.1186/s12886-019-1104-3-
dc.textversionpublisher-
dc.identifier.artnum95-
dc.addressDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicineen
dc.addressDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicineen
dc.addressDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicineen
dc.addressDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicineen
dc.addressDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicineen
dc.identifier.pmid31014297-
dcterms.accessRightsopen access-
datacite.awardNumber17H06820-
dc.identifier.eissn1471-2415-
jpcoar.funderName日本学術振興会ja
jpcoar.funderName.alternativeJapan Society for the Promotion of Science (JSPS)en
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。